Dube Eric M 4

What Happened
Eric M. Dube, CEO of Travere Therapeutics (TVTX), exercised 60,000 stock options (paid $15.46/share, total cost $927,600) and on the same day sold the 60,000 acquired shares in two open-market transactions for combined proceeds of $1,855,839 (34,902 shares at a $30.55 weighted avg; 25,098 shares at a $31.46 weighted avg). The transaction was reported on Form 4 with an effective transaction date of April 1, 2026 and filing date April 2, 2026.

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 2, 2026 (timely filing of provided data).
• Exercise: 60,000 shares acquired at $15.46/share = $927,600.
• Sales: 34,902 shares for $1,066,256 (weighted avg $30.55; price range $30.13–$31.07) and 25,098 shares for $789,583 (weighted avg $31.46; price range $31.15–$31.67). Total sale proceeds ≈ $1,855,839.
• Net cash flow before costs/taxes (sales proceeds minus exercise cost) ≈ $928,239.
• Footnotes: Sales were made under a Rule 10b5-1 trading plan adopted June 16, 2025 and relate to shares underlying a Jan 31, 2020 option grant; the option was fully vested. Per the filing, detailed per-price allocations are available upon request.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.

Context

• This was an exercise of vested options followed by the sale of the same number of shares the same day—effectively a cashless exercise (exercise + immediate sale).
• The sales were executed under a pre-established 10b5-1 plan, which is commonly used to automate insider sales and reduce questions about trading timing.
• Facts only—no inference about management views is made; purchases are generally more indicative of insider bullishness than routine option exercises followed by sales.